Lanwei Medical: 2025 Annual Report

SZSIApr 29 00:00 · Announcements

Lanwei Medical: Summary of the 2025 Annual Report

SZSIApr 29 00:00 · Announcements

Lanwei Medical: First Quarter Report for 2026

SZSIApr 29 00:00 · Announcements

Lanwei Medical (301060.SZ): Estimated net loss of 20 to 38 million yuan in 2025

Gelonghui, January 28th: Lanwei Medical (301060.SZ) announced that the estimated net profit attributable to shareholders of the listed company for 2025 will be between -RMB 38 million and -RMB 20 million. The net profit after deducting non-recurring gains and losses will be between -RMB 55 million and -RMB 29 million. During the reporting period, the company proactively aligned with national policies and industry development trends, promoting the optimization of its business structure and the upgrade of regional integration operations. The company continued to strengthen its two core businesses: medical testing and pathology diagnosis services, as well as in vitro diagnostic product sales. It steadily advanced the implementation of key projects such as the construction of a standardized dataset for digital pathology slide annotations.

Gelonghui FinanceJan 28 20:13

Lanwei Medical: 2025 Annual Performance Forecast

SZSIJan 28 18:52 · Announcements

Express News | The healthcare services sector of the A-share market continued to rise at the opening, with Puruisi surging over 14% to hit an intraday high. Xinlicheng achieved two consecutive trading limit-ups, while International Medical hit the upper price limit. Bos

BreakingsJan 14 09:41